Impact Factor 6.244 | CiteScore 3.9
More on impact ›

RETRACTION article

Front. Oncol., 29 June 2021 | https://doi.org/10.3389/fonc.2021.721658

Retraction: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Squamous Cell Carcinoma by Down-Regulating NF-kB/COX-2/VEGF Pathway

Frontiers Editorial Office*
  • Frontiers Media SA, Lausanne, Switzerland

A Retraction of the Original Research Article
Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway

by Liao, X., Gao, Y., Liu, J., Tao, L., Xie, J., Gu, Y., Liu, T., Wang, D., Xie, D., Mo, S. (2020). Front. Oncol. 10:1756. doi: 10.3389/fonc.2020.01756

The Journal retracts the September 10, 2020 article cited above for the following reason:

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors did not agree to this retraction.

Citation: Frontiers Editorial Office (2021) Retraction: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Squamous Cell Carcinoma by Down-Regulating NF-kB/COX-2/VEGF Pathway. Front. Oncol. 11:721658. doi: 10.3389/fonc.2021.721658

Received: 07 June 2021; Accepted: 07 June 2021;
Published: 29 June 2021.

Approved by:

Olivier Feron, Université catholique de Louvain, Belgium

Copyright © 2021 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, editorial.office@frontiersin.org